Ocular Adnexal Non-Hodgkin Lymphoma — Trials

Ocular Adnexal Non-Hodgkin Lymphoma — Trials · CancerIndex

Clinical trials

Registered studies

4 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 2
Recruiting: 1
Ph III recruiting: 0
Growth YoY: —
Industry share: 0%
Top sponsor: City of Hope Medical Center
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (0)

clinicaltrialsPublishedShowing 1–1 of 1 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT01514344	Intralesional Rituximab for the Treatment of Conjunctival Indolent Lymphoma(IRIS)	completed	Phase 2	20	Andres J. M. FerreriOTHER	1	Aug 4, 2022	clinicaltrials

Data updated 22 days agoSource updated Aug 4, 2022source: clinicaltrials